Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life

Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Planas, Raquel, Martin, Roland, Sospedra, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983075/
https://www.ncbi.nlm.nih.gov/pubmed/24741337
http://dx.doi.org/10.2147/PROM.S41768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983075/
https://www.ncbi.nlm.nih.gov/pubmed/24741337
http://dx.doi.org/10.2147/PROM.S41768

Ejemplares similares